The majority of estrogen receptor (ER)-positive breast cancers are treated with endocrine
therapy. While this is effective, acquired resistance to therapies targeted against ER is a major …

Retinoblastoma (RB; encoded by RB1) is a tumor suppressor that is frequently disrupted in
tumorigenesis and acts in multiple cell types to suppress cell cycle progression. The role of …

BACKGROUND & AIMS: Hepatocellular carcinoma is the third leading cause of cancer mortality
worldwide; current chemotherapeutic interventions for this disease are largely ineffective…

Triple negative breast cancer (TNBC) is characterized by a lack in estrogen, progesterone,
and epidermal growth factor 2 receptors. TNBC exhibits most of the characteristics of basal‐…

Simple Summary The application of immunotherapies to treat cancer patients has significantly
improved over the last two decades and extended many patients’ life spans. Monoclonal …

RB loss occurs commonly in neoplasia but its contributions to advanced cancer have not
been assessed directly. Here we show that RB loss in multiple murine models of cancer …

This study identifies stage-specific consequences of RB loss across cancer progression that
have a direct impact on tumor response to clinically utilized therapeutics. The study herein is …

Advancements in cancer therapy increased the cancer free survival rates and reduced the
malignant related deaths. Therapeutic options for patients with thoracic cancers include …

Sex differences in drug metabolism have been reported in numerous species, including
humans. In rats and mice, sex-dependent differences in circulating growth hormone profiles are …

Purpose: The retinoblastoma tumor suppressor (RB), a key regulator of cell-cycle progression
and proliferation, is functionally suppressed in up to 50% of non–small cell lung cancer (…